Dali Foods Group and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlook of their businesses. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.

Dali Foods Group Company Limited (SEHK:3799)

Dali Foods Group Company Limited manufactures and sells food and beverages in Mainland China. Founded in 1989, and run by CEO Shihui Xu, the company currently employs 35,683 people and with the market cap of HKD HK$102.98B, it falls under the large-cap group.

3799’s projected future profit growth is a robust 15.22%, with an underlying 27.38% growth from its revenues expected over the upcoming years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 26.36%. 3799’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Should you add 3799 to your portfolio? Check out its fundamental factors here.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (SEHK:1349)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. Founded in 1996, and currently run by Haibo Wang, the company now has 621 employees and with the company’s market cap sitting at HKD HK$3.17B, it falls under the mid-cap stocks category.

1349 is expected to deliver an extremely high earnings growth over the next couple of years of 34.00%, driven by a positive double-digit revenue growth of 23.89% and cost-cutting initiatives. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 20.12%. 1349 ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Should you add 1349 to your portfolio? Take a look at its other fundamentals here.